News Release
View printer-friendly version
|
<< Back |
ZUG,
"Steve's extensive experience in regulatory strategy and operations across multiple therapeutic areas and geographies will be a tremendous addition to the CRISPR team," said
During his career, Dr. Caffé has demonstrated exceptional leadership in global regulatory affairs. He has contributed to over 40 new drug approvals and major new indications worldwide in a wide range of therapeutic areas including oncology, hematology, cardiology and rare diseases. Prior to joining
About
CRISPR Forward-Looking Statement
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the timing of filing of clinical trial applications and INDs, any approvals thereof and timing of commencement of clinical trials, the intellectual property coverage and positions of the Company, its licensors and third parties, the sufficiency of the Company’s cash resources and the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the Company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; uncertainties inherent in the initiation and completion of preclinical studies for the Company’s product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K, and in any other subsequent filings made by the Company with the U.S. Securities and Exchange Commission (
MEDIA CONTACT:
WCG for CRISPR
347-658-8290
jpaganelli@wcgworld.com
INVESTOR CONTACTS:
617-307-7227
chris.erdman@crisprtx.com
Westwicke Partners for CRISPR
339-970-2843
chris.brinzey@westwicke.com
Source: CRISPR Therapeutics AG